Cargando…
Commercialized Blood-, Urinary- and Tissue-Based Biomarker Tests for Prostate Cancer Diagnosis and Prognosis
SIMPLE SUMMARY: In prostate cancer diagnosis and prognosis, clinicians often must take decisions on which prostate cancer-suspected patients should undergo biopsy and which prostate cancer-diagnosed patients should undergo treatment, to overcome overdiagnosis and overtreatment. Many biomarker-based...
Autores principales: | Visser, Wieke C. H., de Jong, Hans, Melchers, Willem J. G., Mulders, Peter F. A., Schalken, Jack A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7765473/ https://www.ncbi.nlm.nih.gov/pubmed/33339117 http://dx.doi.org/10.3390/cancers12123790 |
Ejemplares similares
-
Clinical use of the mRNA urinary biomarker SelectMDx test for prostate cancer
por: Visser, Wieke C. H., et al.
Publicado: (2022) -
Prostate Cancer Liquid Biopsy Biomarkers’ Clinical Utility in Diagnosis and Prognosis
por: Matuszczak, Milena, et al.
Publicado: (2021) -
PCA3 and TMPRSS2-ERG: Promising Biomarkers in Prostate Cancer Diagnosis
por: Salagierski, Maciej, et al.
Publicado: (2010) -
Clinically significant Prostate Cancer diagnosed using a urinary molecular biomarker-based risk score: two case reports
por: Minnee, Pieter, et al.
Publicado: (2019) -
Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve men
por: Hendriks, Rianne J., et al.
Publicado: (2021)